Switzerland's Bachem H1 sales rise 4.3% on growth in clinical drug development

BACHEM HOLDING AG

30/07/2026 06:06

Overview
Switzerland peptide maker's H1 sales rose 4.3% yr/yr to CHF 326.4 mln
EBITDA margin fell to 25.4% as ramp-up costs for Building K weighed on profitability
Company expects 35-40% sales growth in local currencies for 2026

Outlook
Bachem expects 2026 sales growth of 35%-40% in local currencies
Company confirms 2026 EBITDA margin in local currencies in the low thirties
Bachem plans investments of CHF 350 mln-400 mln in 2026

Result Drivers
BUILDING K RAMP-UP - Co said ramp-up costs for new large-scale production facility weighed on profitability
SEGMENT PERFORMANCE - Strong sales growth in clinical drug development and research chemicals, but commercial API sales declined
CAPACITY EXPANSION - Ongoing investments in production capacity contributed to higher costs

Company press release: ID:nNFC5CcPWT

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Sales
Beat
CHF 326.40 mln
CHF 316.50 mln (2 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for BACHEM HOLDING AG is CHF80.00, about 8.7% above its July 29 closing price of CHF73.60
The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 26 three months ago

Reuters Recommended Reads
July 29 - France's EuroAPI H1 net sales fall on product discontinuations
July 28 - Repligen Q2 revenue beats estimates on higher orders; raises outlook
July 29 - Avantor Q2 results beat, raises 2026 outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)